Oppenheimer Initiates Coverage On Collegium Pharmaceutical with Outperform Rating, Announces Price Target of $50
Oppenheimer analyst Les Sulewski initiates coverage on Collegium Pharmaceutical (NASDAQ:COLL) with a Outperform rating and announces Price Target of $50.
Share
Why It Matters
A well-known analyst firm just started following Collegium Pharmaceutical and said it looks good. They think the stock could be worth around fifty dollars based on their research.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.